daily oral glp-1 receptor agonist orforglipron for adults with obesity New pill reduces weight in trial Orforglipron Shows Positive Efficacy, Tolerability

doi: 10.1016/j.mce.2007.06.003

This study should be interpreted in the context of several limitations, including (1) the impact of spelling errors on discussion mislabeling, (2) the inability to adjudicate reported side effects, (3) the demographic characteristics of Reddit authors which may limit generalizability, and (4) use of pre-existing general task benchmarks to drive LLM choice that may not optimally generalize to the topic labeling task

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)a multicentre, double-blind, randomised, placebo-controlled trial

The intensive treatment of the multiple risk factors reduces the development/progression of renal disease18 which is why guidelines insist on comprehensive management of the patient with diabetes (glycemic control and control of cardiovascular risk factors, use of renin-angiotensin system inhibitors, as well as lifestyle changes, including smoking cessation or weight loss in overweight/obese individuals, among others).19 However, the residual renal risk remains very high in optimally treated patients.20 More recently, iSGLT2 has been shown to reduce the risk of cardiovascular and renal events, but still, the residual risk of renal disease progression remains high.21,22 Nevertheless, although the rate of diabetes-related complications (such as myocardial infarction, stroke, lower limb amputations or mortality) have decreased significantly in recent decades, this is not the same for CKD patients requiring renal replacement therapy attributed to diabetic kidney disease (DKD).23 Therefore new treatments are needed that improve glycemic control independently of GFR, with a low risk of hypoglycemia and able to reduce cardiovascular and renal risk in this population

It also has another obesity drug moving to late-stage clinical trials, eloralintide, with promising data that further builds on [Lillys] leadership position in the obesity and Type 2 diabetes market, according to a Nov

Drug companies are scrambling for the biggest piece of that profitable pie